State Street’s Galera Therapeutics, Inc. Common Stock GRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-106,564
| Closed | -$14.9K | – | 4428 |
|
|
2024
Q1 | $14.9K | Hold |
106,564
| – | – | ﹤0.01% | 4311 |
|
|
2023
Q4 | $15.5K | Hold |
106,564
| – | – | ﹤0.01% | 4365 |
|
|
2023
Q3 | $18.7K | Buy |
106,564
+12,400
| +13% | +$15.4K | ﹤0.01% | 4452 |
|
|
2023
Q2 | $294K | Buy |
94,164
+11,400
| +14% | +$33.9K | ﹤0.01% | 3881 |
|
|
2023
Q1 | $212K | Buy |
82,764
+54,000
| +188% | +$111K | ﹤0.01% | 4059 |
|
|
2022
Q4 | $42.9K | Hold |
28,764
| – | – | ﹤0.01% | 4591 |
|
|
2022
Q3 | $50K | Hold |
28,764
| – | – | ﹤0.01% | 4658 |
|
|
2022
Q2 | $37K | Hold |
28,764
| – | – | ﹤0.01% | 4785 |
|
|
2022
Q1 | $68K | Buy |
28,764
+2,900
| +11% | +$7.55K | ﹤0.01% | 4738 |
|
|
2021
Q4 | $119K | Hold |
25,864
| – | – | ﹤0.01% | 4536 |
|
|
2021
Q3 | $209K | Buy |
25,864
+9,900
| +62% | +$84.9K | ﹤0.01% | 4339 |
|
|
2021
Q2 | $157K | Sell |
15,964
-111,977
| -88% | -$910K | ﹤0.01% | 4270 |
|
|
2021
Q1 | $1.13M | Buy |
127,941
+6,800
| +6% | +$74.7K | ﹤0.01% | 3595 |
|
|
2020
Q4 | $1.24M | Buy |
121,141
+38,369
| +46% | +$420K | ﹤0.01% | 3520 |
|
|
2020
Q3 | $748K | Sell |
82,772
-2,649
| -3% | -$21K | ﹤0.01% | 3507 |
|
|
2020
Q2 | $610K | Buy |
85,421
+70,337
| +466% | +$747K | ﹤0.01% | 3513 |
|
|
2020
Q1 | $143K | Buy |
+15,084
| New | +$194K | ﹤0.01% | 3597 |
|
Other funds holding GRTX
State Street's GRTX Position: Q2 2024 in Review
State Street sold out of Galera Therapeutics, Inc. Common Stock (GRTX) in Q2 2024, closing a stake of 106,564 shares — an estimated $14.9K sold.
State Street first reported a position in GRTX in Q1 2020 and held it in 17 quarters. The position peaked at $1.24M in Q4 2020. 1 fund tracked by Wall St. Rank holds GRTX as of Q2 2024.
- State Street reported no remaining Galera Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- State Street sold 106,564 Galera Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $14.9K.
- State Street first reported a position in Galera Therapeutics, Inc. Common Stock in Q1 2020 and held it in 17 quarters.
- State Street's Galera Therapeutics, Inc. Common Stock position peaked at $1.24M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Galera Therapeutics, Inc. Common Stock as of Q2 2024.
Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.